Indivior PLC (NASDAQ:INDV) Given Consensus Rating of “Moderate Buy” by Brokerages

Indivior PLC (NASDAQ:INDV) has received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $45.1667.

Several equities analysts have weighed in on the company. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 21st. Barclays dropped their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $53.00 target price on shares of Indivior in a research note on Tuesday, August 4th.

Indivior Stock Down 1.1%

INDV opened at $34.56 on Wednesday. Indivior has a 52 week low of $22.22 and a 52 week high of $42.81. The business has a fifty day simple moving average of $39.16 and a 200-day simple moving average of $36.02. The firm has a market cap of $4.08 billion, a P/E ratio of 12.39 and a beta of 0.82.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The firm had revenue of $343.00 million for the quarter. Sell-side analysts expect that Indivior will post 3.66 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the purchase, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at $986,400.22. This trade represents a 5.74% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. This trade represents a 8.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Trading of Indivior

Hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after purchasing an additional 1,076 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Indivior during the 2nd quarter worth $63,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.